7 Dec 2015 07:00
7 December 2015 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Share Options
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that on 4th December 2015 it awarded 2,000,000 share options to Andrew Franklin, the Chief Financial Officer (the "Options"). The Options have an exercise price of 46.75p and vest on 4th December 2018 subject to the achievement of certain performance conditions. The Options represent 0.76% of the current issued ordinary share capital of the Company and will represent 0.43% of the enlarged issued share capital (assuming the maximum number of shares are issued under the Placing and Placing Option announced on 26th November 2015).
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive | |
Sarah Robinson, Company Secretary | |
www.alliancepharma.co.uk | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Sophie Cowles / Jane Glover | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Freddie Barnfield | |
Corporate Broking: David Poutney / James Black |
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Alliance Pharma (APH)